LGP
BCTX

Leonard Green & Partners’s Briacell Therapeutics BCTX Stock Holding History

Leonard Green & Partners’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,333
Closed -$5.07M – 17
2022
Q1 		$5.07M Buy
+3,333
New +$3.94M 0.03% 41

Other funds holding BCTX

KJHP
K.J. Harrison & Partners Toronto, Ontario, Canada $608M AUM 45.31% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $366M AUM 10.64% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
STA
Summit Trail Advisors New York $6.98B AUM 19.51% 1-Year Est. Return
BCM
Bluefin Capital Management New York $156M AUM 18.42% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Leonard Green & Partners's BCTX Position: Q2 2022 in Review

Leonard Green & Partners sold out of Briacell Therapeutics (BCTX) in Q2 2022, closing a stake of 3,333 shares — an estimated $5.07M sold.

Leonard Green & Partners first reported a position in BCTX in Q1 2022 and held it in 1 quarter. The position peaked at $5.07M in Q1 2022. 20 funds tracked by Wall St. Rank hold BCTX as of Q2 2022.

  • Leonard Green & Partners reported no remaining Briacell Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Leonard Green & Partners sold 3,333 Briacell Therapeutics shares in Q2 2022, an estimated $5.07M.
  • Leonard Green & Partners first reported a position in Briacell Therapeutics in Q1 2022 and held it in 1 quarter.
  • Leonard Green & Partners's Briacell Therapeutics position peaked at $5.07M in Q1 2022.
  • 20 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q2 2022.

Based on Leonard Green & Partners's 13F filing for Q2 2022, filed 15 Aug 2022.